HK32682A - 2-piperazinyl-6,7-dimethoxyquinazolines - Google Patents

2-piperazinyl-6,7-dimethoxyquinazolines

Info

Publication number
HK32682A
HK32682A HK326/82A HK32682A HK32682A HK 32682 A HK32682 A HK 32682A HK 326/82 A HK326/82 A HK 326/82A HK 32682 A HK32682 A HK 32682A HK 32682 A HK32682 A HK 32682A
Authority
HK
Hong Kong
Prior art keywords
dimethoxyquinazolines
piperazinyl
Prior art date
Application number
HK326/82A
Other languages
English (en)
Inventor
William Lesley Matier
John David Catt
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of HK32682A publication Critical patent/HK32682A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK326/82A 1976-02-18 1982-07-15 2-piperazinyl-6,7-dimethoxyquinazolines HK32682A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/659,059 US4060615A (en) 1976-02-18 1976-02-18 2-Piperazinyl-6,7-dimethoxyquinazolines

Publications (1)

Publication Number Publication Date
HK32682A true HK32682A (en) 1982-07-23

Family

ID=24643862

Family Applications (1)

Application Number Title Priority Date Filing Date
HK326/82A HK32682A (en) 1976-02-18 1982-07-15 2-piperazinyl-6,7-dimethoxyquinazolines

Country Status (22)

Country Link
US (1) US4060615A (fr)
JP (1) JPS52100479A (fr)
AU (1) AU505080B2 (fr)
BE (1) BE851447A (fr)
CA (1) CA1090803A (fr)
CH (2) CH620925A5 (fr)
CY (1) CY1155A (fr)
DE (1) DE2707068A1 (fr)
DK (1) DK144010C (fr)
FI (1) FI64586C (fr)
FR (1) FR2341576A1 (fr)
GB (1) GB1545697A (fr)
HK (1) HK32682A (fr)
IE (1) IE44613B1 (fr)
KE (1) KE3221A (fr)
LU (1) LU76779A1 (fr)
MY (1) MY8300172A (fr)
NL (1) NL7701584A (fr)
SE (1) SE431753B (fr)
SG (1) SG30882G (fr)
YU (4) YU42577A (fr)
ZA (1) ZA77587B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
JPS6016948B2 (ja) * 1978-03-29 1985-04-30 住友化学工業株式会社 新規なキナゾリン誘導体及びその製造法
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0022481A1 (fr) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. Dérivés de la 5,6-alcoylènepyrimidine, procédés pour leur préparation et préparations pharmaceutiques
US4426382A (en) * 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3304292A1 (de) * 1982-10-11 1984-04-12 Brown, Boveri & Cie Ag, 6800 Mannheim Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
AT384218B (de) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Verfahren zur herstellung von neuen chinazolin-derivaten
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
CA2077252C (fr) * 1992-08-31 2001-04-10 Khashayar Karimian Methodes de fabrication d'urees et de guanidines et composes intermediaires servant a ces syntheses
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
CA2238283C (fr) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
MXPA03010119A (es) * 2001-05-09 2005-03-07 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas 2-fenilo sustituidas.
EP1312363A1 (fr) * 2001-09-28 2003-05-21 Pfizer Products Inc. Méthode de traitement et kit comprenant un secrétagogue d'hormone de croissance
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
MXPA04009997A (es) * 2002-04-12 2004-12-13 Celgene Corp Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
CN1658848A (zh) * 2002-04-12 2005-08-24 细胞基因公司 血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
SG166106A1 (en) * 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
SI2049500T1 (sl) 2006-07-06 2012-01-31 Array Biopharma Inc Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji
DK2054418T3 (da) 2006-07-06 2012-02-27 Array Biopharma Inc Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2656566C (fr) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines comme inhibiteurs de la proteine kinase akt
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
AU2008272832B2 (en) * 2007-07-05 2014-02-20 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2422733T3 (es) * 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
JP5539225B2 (ja) * 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
WO2009120296A1 (fr) * 2008-03-24 2009-10-01 Celgene Corporation Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-3-oxoisoindoline-4-yl}carboxamide
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
ES2688809T3 (es) 2011-04-01 2018-11-07 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
WO2019010180A1 (fr) * 2017-07-06 2019-01-10 Case Western Reserve University Agonistes peptidiques et à petites molécules d'epha et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
JPS536156B2 (fr) * 1972-10-30 1978-03-04
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives

Also Published As

Publication number Publication date
CH623051A5 (fr) 1981-05-15
ZA77587B (en) 1977-12-28
US4060615A (en) 1977-11-29
AU505080B2 (en) 1979-11-08
JPS52100479A (en) 1977-08-23
YU40622B (en) 1986-02-28
SE7701731L (sv) 1977-08-19
IE44613L (en) 1977-08-18
KE3221A (en) 1982-08-13
FI770486A (fr) 1977-08-19
CY1155A (en) 1983-01-28
IE44613B1 (en) 1982-01-27
YU165282A (en) 1982-10-31
FI64586B (fi) 1983-08-31
FR2341576B1 (fr) 1979-01-19
FI64586C (fi) 1983-12-12
CA1090803A (fr) 1980-12-02
NL7701584A (nl) 1977-08-22
DK65077A (da) 1977-08-19
YU165482A (en) 1982-10-31
CH620925A5 (fr) 1980-12-31
DK144010C (da) 1982-04-26
YU165382A (en) 1982-10-31
BE851447A (fr) 1977-08-16
AU2189777A (en) 1978-08-10
LU76779A1 (fr) 1977-08-19
DE2707068A1 (de) 1977-09-01
SE431753B (sv) 1984-02-27
DK144010B (da) 1981-11-16
SG30882G (en) 1983-07-08
MY8300172A (en) 1983-12-31
YU42577A (en) 1982-10-31
GB1545697A (en) 1979-05-10
FR2341576A1 (fr) 1977-09-16

Similar Documents

Publication Publication Date Title
MY8300172A (en) 2-piperazinyl-6,7-dimethoxyquinazolines
PH13932A (en) 1,2,3,4-tetrahydro-napthalenes
GB1524917A (en) Gona-1,9(10)-dienes
NZ183143A (en) 2-aminoakyl-1,2-benzisothiazol 3-anes
GB1542569A (en) 2-substituted-15-heteroaryl-16,17,18,19,20-pentanor-prostaglandins
GB1556570A (en) 1,5-disubstituted - 2 - pyrrolidones
IL52424A0 (en) 2,6-methano-2h-1-benzoxocins
AU2468877A (en) 1,4 -dicyanobytene
PH14105A (en) 1,2,3-thiadiazol-5-yl-ureas
JPS52108209A (en) Type
PH15728A (en) 1-amino-lower-alkyl-3,4-diphenyl-1h-pyrazoles
GB1537635A (en) 15,16-dihydroxyprostaglandins
IL53527A (en) N1-chloro-3,5-dinitrosulfanilamides
NZ184082A (en) 1-benzothiazol-2yl-1,3-imidazolidin-2-ones
GB1554049A (en) 2-decarboxy-2-hydroxymethyl-13,14-didehydroprostaglandins
GB1547729A (en) 1-phenyl-4-acetoxy-1,2-dihydroquinolin-2-ones
JPS5349526A (en) Type
GB1541820A (en) 1,4-oxathianes
AU3178777A (en) Substituted 4,5-dihydroxy-imidazolidine-2-thiones
EG12897A (en) N,n,methylebebis-co,o-diaryl-n-phosphonomethylglycinonitrilles
GB1554045A (en) 13,14-didehydroprostaglandins
ZA774088B (en) 2,5-dichloro-4-bromphenylazo-4-chloro-phenyl-sulphide
IE812329L (en) N, n-bisphenylethylamines
IE790331L (en) N2-arylsulphonyl-l-argininamides.
IE812708L (en) 7-amino-cephalosporins.